1 Shane B (2000) Folate, vitamin B12, and vitamin B6. In Biochemical and Physiological Aspects of Human Nutrition, pp. 483–518 [Stipanuk M, editor]. Philadelphia, PA: WB Saunders.
2 Stickel F, Choi SW, Kim YI, et al. (2000) Effect of chronic alcohol consumption on total plasma homocysteine level in rats. Alcohol Clin Exp Res 24, 259–264.
3 Parker TH, Marshall JP 2nd, Roberts RK, et al. (1979) Effect of acute alcohol ingestion on plasma pyridoxal 5′-phosphate. Am J Clin Nutr 32, 1246–1252.
4 Lui A, Lumeng L, Aronoff GR, et al. (1985) Relationship between body store of vitamin B6 and plasma pyridoxal-P clearance: metabolic balance studies in humans. J Lab Clin Med 106, 491–497.
5 Bode W, Mocking JA & van den Berg H (1991) Influence of age and sex on vitamin B-6 vitamer distribution and on vitamin B-6 metabolizing enzymes in Wistar rats. J Nutr 121, 318–329.
6 Lumeng L, Lui A & Li TK (1980) Plasma content of B6 vitamers and its relationship to hepatic vitamin B6 metabolism. J Clin Invest 66, 688–695.
7 Leklem JE (1990) Vitamin B-6: a status report. J Nutr 120, Suppl. 11, 1503–1507.
8 Mason JB (2003) Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr 133, Suppl. 3, 941S–947S.
9 Food and Nutrition Board – Institute of Medicine (1998) Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press.
10 Pasceri V & Yeh ET (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100, 2124–2126.
11 Friso S, Girelli D, Martinelli N, et al. (2004) Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. Am J Clin Nutr 79, 992–998.
12 Fairfield KM & Fletcher RH (2002) Vitamins for chronic disease prevention in adults: scientific review. JAMA 287, 3116–3126.
13 Friso S, Jacques PF, Wilson PW, et al. (2001) Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103, 2788–2791.
14 Willerson JT & Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109, Suppl. 1, II2–II10.
15 Chiang EP, Bagley PJ, Roubenoff R, et al. (2003) Plasma pyridoxal 5′-phosphate concentration is correlated with functional vitamin B-6 indices in patients with rheumatoid arthritis and marginal vitamin B-6 status. J Nutr 133, 1056–1059.
16 Saibeni S, Cattaneo M, Vecchi M, et al. (2003) Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 98, 112–117.
17 Roubenoff R, Roubenoff RA, Selhub J, et al. (1995) Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 38, 105–109.
18 Chiang EP, Smith DE, Selhub J, et al. (2005) Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 7, R1254–R1262.
19 Chiang EP, Bagley PJ, Selhub J, et al. (2003) Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 114, 283–287.
20 Monson RR & Hall AP (1976) Mortality among arthritics. J Chronic Dis 29, 459–467.
21 Mikuls TR & Saag KG (2001) Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 27, 283–303.
22 del Rincon ID, Williams K, Stern MP, et al. (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44, 2737–2745.
23 Snow MH & Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17, 234–241.
24 Chiang EP, Selhub J, Bagley PJ, et al. (2005) Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther 7, R1404–R1411.
25 Ross R (1999) Atherosclerosis – an inflammatory disease. N Engl J Med 340, 115–126.
26 Libby P, Ridker PM & Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54, 2129–2138.
27 Robinson K, Mayer EL, Miller DP, et al. (1995) Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 92, 2825–2830.
28 Selhub J, Jacques PF, Bostom AG, et al. (1995) Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332, 286–291.
29 Kelly PJ, Shih VE, Kistler JP, et al. (2003) Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 34, e51–e54.
30 Robinson K, Arheart K, Refsum H, et al. (1998) Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 97, 437–443.
31 Folsom AR, Nieto FJ, McGovern PG, et al. (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 98, 204–210.
32 Dalery K, Lussier-Cacan S, Selhub J, et al. (1995) Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 75, 1107–1111.
33 Folsom AR, Chambless LE, Ballantyne CM, et al. (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166, 1368–1373.
34 Verhoef P, Kok FJ, Kruyssen DA, et al. (1997) Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 17, 989–995.
35 Siri PW, Verhoef P, Kok FJ, et al. (1998) Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. J Am Coll Nutr 17, 435–441.
36 Lin PT, Cheng CH, Liaw YP, et al. (2006) Low pyridoxal 5′-phosphate is associated with increased risk of coronary artery disease. Nutrition 22, 1146–1151.
37 Cheng CH, Lin PT, Liaw YP, et al. (2008) Plasma pyridoxal 5′-phosphate and high-sensitivity C-reactive protein are independently associated with an increased risk of coronary artery disease. Nutrition 24, 239–244.
38 Kok FJ, Schrijver J, Hofman A, et al. (1989) Low vitamin B6 status in patients with acute myocardial infarction. Am J Cardiol 63, 513–516.
39 Labadarios D & Weich HF (1987) Vitamin B6 – in search of a clinical perspective. S Afr Med J 71, 549–550.
40 Iqbal MP, Ishaq M, Kazmi KA, et al. (2005) Role of vitamins B6, B12 and folic acid on hyperhomocysteinemia in a Pakistani population of patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis 15, 100–108.
41 Vermaak WJ, Barnard HC, Potgieter GM, et al. (1986) Plasma pyridoxal-5′-phosphate levels in myocardial infarction. S Afr Med J 70, 195–196.
42 Chasan-Taber L, Selhub J, Rosenberg IH, et al. (1996) A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 15, 136–143.
43 Tavani A, Pelucchi C, Parpinel M, et al. (2004) Folate and vitamin B(6) intake and risk of acute myocardial infarction in Italy. Eur J Clin Nutr 58, 1266–1272.
44 Page JH, Ma J, Chiuve SE, et al. (2009) Plasma vitamin B(6) and risk of myocardial infarction in women. Circulation 120, 649–655.
45 Gallant JE, Staszewski S, Pozniak AL, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292, 191–201.
46 Verhoef P, Stampfer MJ, Buring JE, et al. (1996) Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 143, 845–859.
47 Dierkes J, Weikert C, Klipstein-Grobusch K, et al. (2007) Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort. Am J Clin Nutr 86, 214–220.
48 Nahlawi M, Seshadri N, Boparai N, et al. (2002) Usefulness of plasma vitamin B(6), B(12), folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients. Am J Cardiol 89, 834–837.
49 Vermaak WJ, Barnard HC, Van Dalen EM, et al. (1988) Compartmentalization of pyridoxal-5′-phosphate during the acute phase of myocardial infarction. Klin Wochenschr 66, 428–433.
50 Kelly PJ, Kistler JP, Shih VE, et al. (2004) Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. Stroke 35, 12–15.
51 Willett W (1998) Nutritional Epidemiology. New York, NY: Oxford University Press.
52 He K, Merchant A, Rimm EB, et al. (2004) Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 35, 169–174.
53 Medrano MJ, Sierra MJ, Almazan J, et al. (2000) The association of dietary folate, B6, and B12 with cardiovascular mortality in Spain: an ecological analysis. Am J Public Health 90, 1636–1638.
54 Wilmink AB, Welch AA, Quick CR, et al. (2004) Dietary folate and vitamin B6 are independent predictors of peripheral arterial occlusive disease. J Vasc Surg 39, 513–516.
55 Ellis JM & McCully KS (1995) Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol 89, 208–220.
56 Rimm EB, Willett WC, Hu FB, et al. (1998) Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279, 359–364.
57 Peeters AC, van Aken BE, Blom HJ, et al. (2007) The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers. Clin Chem Lab Med 45, 54–58.
58 Palmas W (2006) Effects of short-term supplementation with ascorbate, folate, and vitamins B6 and B12 on inflammatory factors and estrogen levels in obese postmenopausal women. Int J Vitam Nutr Res 76, 34–38.
59 Mahfouz MM & Kummerow FA (2004) Vitamin C or vitamin B6 supplementation prevent the oxidative stress and decrease of prostacyclin generation in homocysteinemic rats. Int J Biochem Cell Biol 36, 1919–1932.
60 Toole JF, Sane DC & Bettermann K (2004) Stroke prevention: optimizing the response to a common threat. JAMA 292, 1885–1887.
61 Bønaa KH, Njolstad I, Ueland PM, et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578–1588.
62 Albert CM, Cook NR, Gaziano JM, et al. (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299, 2027–2036.
63 Toole JF, Malinow MR, Chambless LE, et al. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565–575.
64 Marcucci R, Zanazzi M, Bertoni E, et al. (2003) Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 75, 1551–1555.
65 Till U, Rohl P, Jentsch A, et al. (2005) Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis 181, 131–135.
66 Hodis HN, Mack WJ, Dustin L, et al. (2009) High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 40, 730–736.
67 Schnyder G, Roffi M, Pin R, et al. (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345, 1593–1600.
68 Lange H, Suryapranata H, De Luca G, et al. (2004) Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350, 2673–2681.
69 Ebbing M, Bleie O, Ueland PM, et al. (2008) Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 300, 795–804.
70 Lonn E, Yusuf S, Arnold MJ, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567–1577.
71 Loscalzo J (2006) Homocysteine trials – clear outcomes for complex reasons. N Engl J Med 354, 1629–1632.
72 Endo N, Nishiyama K, Otsuka A, et al. (2006) Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br J Nutr 95, 1088–1093.
73 Meydani SN, Hayek M & Coleman L (1992) Influence of vitamins E and B6 on immune response. Ann N Y Acad Sci 669, 125–139, .
74 Anonymous (1981) Is vitamin B6 an antithrombotic agent? Lancet i, 1299–1300.
75 Schoene NW, Chanmugam P & Reynolds RD (1986) Effect of oral vitamin B6 supplementation on in vitro platelet aggregation. Am J Clin Nutr 43, 825–830.
76 Doke S, Inagaki N, Hayakawa T, et al. (1998) Effects of vitamin B6 deficiency on cytokine levels and lymphocytes in mice. Biosci Biotechnol Biochem 62, 1008–1010.
77 Meydani SN, Ribaya-Mercado JD, Russell RM, et al. (1991) Vitamin B-6 deficiency impairs interleukin 2 production and lymphocyte proliferation in elderly adults. Am J Clin Nutr 53, 1275–1280.
78 Kwak HK, Hansen CM, Leklem JE, et al. (2002) Improved vitamin B-6 status is positively related to lymphocyte proliferation in young women consuming a controlled diet. J Nutr 132, 3308–3313.
79 Morris MS, Sakakeeny L, Jacques PF, et al. (2010) Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. J Nutr 140, 103–110.
80 Ridker PM (2001) Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 358, 946–948.
81 Ridker PM, Hennekens CH, Buring JE, et al. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342, 836–843.
82 Grundy SM (1999) Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 100, 988–998.
83 James S, Vorster HH, Venter CS, et al. (2000) Nutritional status influences plasma fibrinogen concentration: evidence from the THUSA survey. Thromb Res 98, 383–394.
84 Heitzer T, Schlinzig T, Krohn K, et al. (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104, 2673–2678.
85 Matsubara K, Matsumoto H, Mizushina Y, et al. (2003) Inhibitory effect of pyridoxal 5′-phosphate on endothelial cell proliferation, replicative DNA polymerase and DNA topoisomerase. Int J Mol Med 12, 51–55.
86 Matsubara K, Mori M, Akagi R, et al. (2004) Anti-angiogenic effect of pyridoxal 5′-phosphate, pyridoxal and pyridoxamine on embryoid bodies derived from mouse embryonic stem cells. Int J Mol Med 14, 819–823.
87 Woolf K & Manore MM (2008) Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. J Am Diet Assoc 108, 443–453, .
88 Folsom AR, Desvarieux M, Nieto FJ, et al. (2003) B Vitamin status and inflammatory markers. Atherosclerosis 169, 169–174.
89 Camp VM, Chipponi J & Faraj BA (1983) Radioenzymatic assay for direct measurement of plasma pyridoxal 5′-phosphate. Clin Chem 29, 642–644.
90 Kimura M, Kanehira K & Yokoi K (1996) Highly sensitive and simple liquid chromatographic determination in plasma of B6 vitamers, especially pyridoxal 5′-phosphate. J Chromatogr A 722, 296–301.
91 Vasilaki AT, McMillan DC, Kinsella J, et al. (2008) Relation between pyridoxal and pyridoxal phosphate concentrations in plasma, red cells, and white cells in patients with critical illness. Am J Clin Nutr 88, 140–146.
92 Shen J, Lai CQ, Mattei J, et al. (2010) Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr 91, 337–342.